Fed. Circ. Bars Generic Of Horizon Arthritis Drug Until 2027

Law360 (October 10, 2019, 7:58 PM EDT) -- A split Federal Circuit on Thursday affirmed a lower court’s decision that upheld the validity of a claim in one of the patents for Horizon’s osteoarthritis drug Pennsaid 2%, a ruling that blocks Actavis from selling a generic version of the drug until late 2027.

In a 55-page, 2-1 precedential opinion, the majority of a three-judge panel said that a New Jersey federal court correctly found that Teva Pharmaceuticals unit Actavis did not infringe most of Horizon’s patents for Pennsaid 2%, a topical formulation used to treat osteoarthritis of the knees, and that several of the claims were invalid for being...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS